Noveome Biotherapeutics, Inc. Announces Appointment of Kevin E. McCracken as Senior Vice President of Operations

PITTSBURGH--()--Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announced the appointment of Kevin E. McCracken, B.S., M.B.A., as Senior Vice President of Operations.

“Kevin brings over two decades of biopharmaceutical operational expertise and we are excited to welcome him to the Noveome team as we begin to shift to a later-stage clinical company and expand the breadth of our leadership team,” said William J. Golden, CFA, Founder, Chairman and CEO of Noveome. “We look forward to Kevin’s strategic insights as we continue to grow Noveome and further refine our scalable manufacturing capabilities.”

“I am thrilled to join Noveome at such an exciting time,” said Mr. McCracken. “In recent years, the company has made great progress exploring the potentially broad applications of ST266 and I look forward to contributing to an efficient clinical and manufacturing progression of ST266 and its diverse application across numerous indications.”

Mr. McCracken joins Noveome with over 24 years of experience in the biopharmaceutical industry, with roles in quality control, quality assurance, validation, manufacturing and supply chain operations. Most recently, Mr. McCracken was the Vice President of Chemistry, Manufacturing and Controls at Kadmon Pharmaceuticals, where he spent 11 years. His additional roles included various quality roles at MedImmune supporting the development, approval and commercial production of Synagis® and other biologics. Mr. McCracken also served as the Director of Quality for Acambis overseeing QA, QC and validation activities at a facility for the aseptic filling of live smallpox vaccine. Mr. McCracken holds a B.S. in Microbiology from the University of Pittsburgh as well as an M.B.A from Frostburg State University.

About Noveome Biotherapeutics, Inc.

Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Noveome’s multi-target platform biologic and lead product, ST266, is currently being evaluated in multiple indications across ophthalmic, CNS, dermatologic, gastrointestinal and pulmonary therapeutic areas. In addition to the Phase 1 open label clinical trial to establish the safety of ST266 when delivered intranasally, Noveome is currently conducting a Phase 2 open-label clinical trial evaluating the efficacy of ST266 in healing PEDs when delivered topically to the eye. Preclinical results testing ST266 in chronic traumatic encephalopathy (CTE), emphysema, polytrauma, and necrotizing enterocolitis (NEC) are expected in late 2019 / early 2020. The Company received seed funding from Lancet Capital, a venture capital consortium of leading Pittsburgh healthcare institutions including UPMC Health System, Highmark Health, University of Pittsburgh and Carnegie Mellon University. To date, Noveome has received over $120 million in research and infrastructure funding from the U.S. Department of Defense, the Commonwealth of Pennsylvania and Allegheny County. Noveome is based in Pittsburgh, PA. For more information, please visit, www.noveome.com.

Contacts

Investors:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie.seidel@sternir.com

Contacts

Investors:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie.seidel@sternir.com